These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27859453)

  • 21. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A New Product Development Partnership Model for Antibiotic Resistance.
    Billington JK
    Am J Law Med; 2016 May; 42(2-3):487-523. PubMed ID: 29086636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
    Talbot GH; Jezek A; Murray BE; Jones RN; Ebright RH; Nau GJ; Rodvold KA; Newland JG; Boucher HW;
    Clin Infect Dis; 2019 Jun; 69(1):1-11. PubMed ID: 30715222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
    Outterson K; Rex JH; Jinks T; Jackson P; Hallinan J; Karp S; Hung DT; Franceschi F; Merkeley T; Houchens C; Dixon DM; Kurilla MG; Aurigemma R; Larsen J
    Nat Rev Drug Discov; 2016 Sep; 15(9):589-590. PubMed ID: 27469032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combating resistance while maintaining innovation: the future of antimicrobial stewardship.
    Vickers RJ; Bassetti M; Clancy CJ; Garey KW; Greenberg DE; Nguyen MH; Roblin D; Tillotson GS; Wilcox MH
    Future Microbiol; 2019 Oct; 14():1331-1341. PubMed ID: 31526186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance diagnosis and the changing economics of antibiotic discovery.
    McAdams D
    Ann N Y Acad Sci; 2017 Jan; 1388(1):18-25. PubMed ID: 28072904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.
    Morel CM; Edwards SE; Harbarth S
    Clin Microbiol Infect; 2017 Oct; 23(10):718-722. PubMed ID: 28811243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 33. An antibiotic's journey from marketing authorization to use, Norway.
    Årdal C; Blix HS; Plahte J; Røttingen JA
    Bull World Health Organ; 2017 Mar; 95(3):220-226. PubMed ID: 28250535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
    Rome BN; Kesselheim AS
    Clin Infect Dis; 2020 Oct; 71(7):1671-1675. PubMed ID: 31630159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations.
    Hey SP; Kesselheim AS
    Hastings Cent Rep; 2017 Mar; 47(2):16-20. PubMed ID: 28301705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late stage antibacterial drugs in the clinical pipeline.
    Projan SJ; Bradford PA
    Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards new business models for R&D for novel antibiotics.
    So AD; Gupta N; Brahmachari SK; Chopra I; Munos B; Nathan C; Outterson K; Paccaud JP; Payne DJ; Peeling RW; Spigelman M; Weigelt J
    Drug Resist Updat; 2011 Apr; 14(2):88-94. PubMed ID: 21439891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibacterial drug discovery: is it all downhill from here?
    Projan SJ; Shlaes DM
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.